Cancer Research and Treatment

Original Articles

CNS cancer

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study): Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim; Cancer Res Treat. 2022;54(2):396-405. Published online July 6, 2021; DOI: https://doi.org/10.4143/crt.2021.393

Abstract PDF Supplementary Material PubReader ePub

Purpose
The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL).
Materials and Methods
In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B).
Results
Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33).
Conclusion
The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.

Citations

Citations to this article as recorded by

Achievements of international rare cancers networks and consortia in the neuro-oncology field
Vincenzo Di Nunno, Enrico Franceschi, Ahmed Idbaih
Current Opinion in Oncology.2024; 36(6): 554. CrossRef
Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review
Jason A. Martin, Nicolas H. Hart, Natalie Bradford, Fiona Naumann, Mark B. Pinkham, Elizabeth P. Pinkham, Justin J. Holland
Journal of Neuro-Oncology.2023; 162(1): 25. CrossRef
Prolonged use of temozolomide leads to increased anxiety and decreased content of aggrecan and chondroitin sulfate in brain tissues of aged rats
Anastasia Strokotova, Dmitry Sokolov, Olga Molodykh, Elena Koldysheva, Evgenii Kliver, Victor Ushakov, Maxim Politko, Nadezhda Mikhnevich, Galina Kazanskaya, Svetlana Aidagulova, Elvira Grigorieva
Biomedical Reports.2023;[Epub] CrossRef

7,931 View
162 Download
4 Web of Science
3 Crossref

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma: Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2014;46(3):261-269. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.261

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.

Citations

Citations to this article as recorded by

A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
Sara Steffanoni, Teresa Calimeri, Nicoletta Anzalone, Sara Mastaglio, Massimo Bernardi, Andrés JM Ferreri
Expert Review of Hematology.2022; 15(1): 33. CrossRef
Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse
Peng Du, Hongyi Chen, Li Shen, Xiao Liu, Xuefan Wu, Lang Chen, Aihong Cao, Daoying Geng
Current Oncology.2022; 29(9): 6642. CrossRef
Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?
Shaani Singhal, Ellathios Antoniou, Edward Kwan, Gareth Gregory, Leon T. Lai
Journal of Clinical Neuroscience.2022; 106: 110. CrossRef
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Journal of Neuro-Oncology.2021; 154(2): 207. CrossRef
Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian
Journal of Biomedical Nanotechnology.2021; 17(8): 1459. CrossRef
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
Tae Hoon Lee, Joo Ho Lee, Ji Hyun Chang, Sung-Joon Ye, Tae Min Kim, Chul-Kee Park, Il Han Kim, Byoung Hyuck Kim, Chan Woo Wee
Radiation Oncology Journal.2020; 38(1): 35. CrossRef
Advances and challenges in the treatment of primary central nervous system lymphoma
Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
Journal of Cellular Physiology.2020; 235(12): 9143. CrossRef
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Jun Su Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Japanese Journal of Clinical Oncology.2017; 47(11): 995. CrossRef
Role of radiation therapy in primary central nervous system lymphoma
Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
Journal of Neuro-Oncology.2017; 135(3): 629. CrossRef

12,590 View
77 Download
10 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search